1. |
國家藥品監督管理局. 真實世界證據支持藥物研發與審評的指導原則(試行). 2023.
|
2. |
Wang SV, Schneeweiss S. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA, 2023, 329(16): 1376-1385.
|
3. |
Sheldrick RC. Randomized trials vs real-world evidence: how can both inform decision-making. JAMA, 2023, 329(16): 1352-1353.
|
4. |
Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon Open, 2021, 5(1): 3-11.
|
5. |
Scavone C, di Mauro G, Mascolo A, et al. The new paradigms in clinical research: from early access programs to the novel therapeutic approaches for unmet medical needs. Front Pharmacol, 2019, 10: 111.
|
6. |
Morales DR, Arlett P. RCTs and real world evidence are complementary, not alternatives. BMJ, 2023, 381: 736.
|
7. |
Purpura CA, Garry EM, Honig N, et al. The role of real-world evidence in fda-approved new drug and biologics license applications. Clin Pharmacol Ther, 2022, 111(1): 135-144.
|
8. |
廖茜雯, 姚晨, 張軍, 等. 真實世界數據和證據在我國臨床決策中的應用現狀. 中國食品藥品監管, 2023, (10): 24-35.
|
9. |
陳薇, 方賽男, 劉建平, 等. 國際循證醫學證據分級體系的發展與現狀. 中國中西醫結合雜志, 2017, 37(12): 1413-1419.
|
10. |
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials, 1996, 17(1): 1-12.
|
11. |
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
|
12. |
曹雪, 孟祥然, 王馨, 等. 真實世界觀察性研究的質量評價工具ArRoWS解讀. 中國循證醫學雜志, 2023, 23(2): 227-232.
|
13. |
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
|
14. |
廖星, 章軼立, 謝雁鳴. 真實世界研究標準: RECORD清單和GRACE清單的解讀. 中國中藥雜志, 2015, 40(24): 4734-4738.
|
15. |
陳英耀, 倪明, 胡獻之, 等. 公立醫療機構公益性評價指標篩選—基于德爾菲專家咨詢法. 中國衛生政策研究, 2012, 5(1): 6-10.
|
16. |
葉瑩, 姬艷芳, 張璐, 等. 運用Likert 5級評分法對免疫規劃互聯網+培訓的效果評價. 河南預防醫學雜志, 2019, 30(9): 701-703.
|
17. |
宋辰斐, 薛征, 吳淑艷, 等. 《藥物香佩療法預防小兒反復呼吸道感染治未病實踐指南》香佩藥物的德爾菲法結果分析. 中華中醫藥雜志, 2017, 32(1): 139-141.
|
18. |
馬雪顏, 于河, 吳力群, 等. 基于德爾菲法的兒童胃腸積熱評價量表條目篩選. 中華中醫藥雜志, 2020, 35(2): 851-854.
|
19. |
肖爽, 朱雪琦, 王彥, 等. 基于德爾菲法的臨床科研課題全過程質量控制指標體系構建研究. 中醫藥管理雜志, 2023, 31(21): 1-6.
|
20. |
Schad F, Thronicke A. Real-world evidence-current developments and perspectives. Int J Environ Res Public Health, 2022, 19(16): 10159.
|
21. |
艾飛玲, 胡葵茹, 石鈺霖, 等. 基于紐卡斯爾-渥太華量表對中國吸煙隊列研究文獻的質量評價. 中華疾病控制雜志, 2021, 25(6): 722-729.
|
22. |
Radenkovic D, Keogh SB, Maruthappu M. Data science in modern evidence-based medicine. J R Soc Med, 2019, 112(12): 493-494.
|
23. |
范美玉. 高質量循證醫學證據獲取與應用研究. 協和醫學雜志, 2023, 14(1): 39-43.
|
24. |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us. N Engl J Med, 2016, 375(23): 2293-2297.
|
25. |
McNair D, Lumpkin M, Kern S, et al. Use of RWE to inform regulatory, public health policy, and intervention priorities for the developing world. Clin Pharmacol Ther, 2022, 111(1): 44-51.
|